Clinical Trials Arena July 26, 2024
Justine Ra

Increasing trial diversity hinges on effective communication with the patient community and optimising site dynamics.

While the topic of clinical trial diversity has been in circulation for some time, it has recently gained traction with the US Food and Drug Administration (FDA) releasing a guidance shepherding sponsors on the implementation of diversity plans.

The FDA’s call to action is meant to improve community trust in clinical trials by considering factors such as site location and community based care that could improve data quality and applicability across diverse patient populations. In a 2023 US Food and Drug Administration (FDA) drug trials snapshots summary assessing demographic representation in clinical trials for the 55 drugs approved in 2023, the Center for Drug...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Clinical Trials, FDA, Govt Agencies, Interview / Q&A, Trends
Amgen starts two critical late-stage trials for weight loss drug MariTide
Anti-CRO Lindus Health Raises $55M in Series B Funding to Transform the Clinical Trial Landscape
EU launches clinical trial map for patients and professionals
Expanding Clinical Trial Access Amid DEI Challenges
Expanding Access to Clinical Trials: What Oncologists and Payers Need to Know

Share This Article